Home › Companies › MGTX

MeiraGTx

Market cap $827M 97.7M shares (10-Q, Nov 4, 2026) × $8.46 close Nov 17, 2026

Most recent annual filing: 2026-03-30

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. Beacon Therapeutics laru-zova VISTA readout2H 2026Beacon Therapeutics laru-zova VISTA readout, 2H 2026, notable
  2. riboswitch oral small molecule trialDec 2026riboswitch oral small molecule trial, Dec 2026, routine
  3. Bota-vec FDA approval2027Bota-vec FDA approval, 2027, material
  4. Bota-vec BLA filing1Q 2027Bota-vec BLA filing, 1Q 2027, notable
  5. AAV-hAQP1 BLA filing1H 2027AAV-hAQP1 BLA filing, 1H 2027, notable
  6. AAV-GAD Ph3 start1Q 2027AAV-GAD Ph3 start, 1Q 2027, routine
  7. AAV-hAQP1 pivotal toplinemid-2027AAV-hAQP1 pivotal topline, mid-2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (16 active programs)

Technology platforms

Riboswitch Gene Regulation Platform

Proprietary synthetic riboswitch technology enabling precise, dose-responsive control of gene expression via oral small molecules; focused on in vivo delivery of metabolic peptides (GLP-1, GIP, glucagon, amylin, PYY, leptin), cell therapy for oncology and autoimmune diseases, and long-term intractable pain

ProTcell

T-cell progenitor-based allogeneic cell therapy platform acquired from Smart Immune; harnesses the patient's own thymus to re-arm the immune system; intended for off-the-shelf allogeneic CAR-T therapies incorporating MeiraGTx riboswitch technology; focus areas include cancer and autoimmune conditions

Riboswitch · Eli Lilly and Company

Proprietary gene regulation platform enabling precise, dose-responsive in vivo delivery of any biologic therapeutic (peptides, hormones, proteins) via oral small molecule inducers. Disease focus areas include metabolic disease (leptin, GLP-1, GIP, Glucagon, Amylin, PYY), cell therapy (CAR-T for liquid/solid tumors and autoimmune diseases), neuropathic/intractable pain, and ophthalmology (gene editing in the eye via Lilly collaboration).

Targets: GLP-1, GIP, Glucagon, Amylin, PYY, Leptin

Gene Regulation

Proprietary synthetic riboswitch technology enabling precise, dose-responsive expression of any transgene controlled by oral small molecules; focused on in vivo delivery of biologic therapeutics (GLP-1, GIP, glucagon, amylin, PYY, leptin), cell therapy for oncology and autoimmune diseases, and long-term intractable pain.

Riboswitch Gene Regulation Technology · Eli Lilly and Company

Broadly applicable gene regulation platform enabling precise, dose-responsive oral small molecule control of transgene expression; gene agnostic and compatible with AAV, lentivirus, CRISPR, or LNP vectors; focus areas include metabolic disease (Ribo-Leptin, GLP-1, GIP, Glucagon, Amylin, PYY, Leptin), neuropathic pain, CAR-T for liquid/solid tumors and autoimmune diseases, and ophthalmology gene editing

Targets: GLP-1, GIP, Glucagon, Amylin, PYY, Leptin

Intravitreal Capsids · Eli Lilly and Company

Proprietary intravitreal AAV capsid platform for ocular gene therapy delivery; licensed to Eli Lilly as part of ophthalmology collaboration.

AI Driven Promoter Platform · Eli Lilly and Company

Artificial intelligence-driven platform for generating bespoke gene promoters for ocular and other gene therapy applications; licensed to Eli Lilly as part of ophthalmology collaboration.

Riboswitch Gene Regulation Platform · Sanofi

Proprietary synthetic riboswitch technology enabling precise, dose-responsive expression of any transgene under control of oral small molecules. Applications include in vivo delivery of metabolic peptides (GLP-1, GIP, glucagon, amylin, PYY, leptin), CAR-T cell therapy for oncology and autoimmune diseases, and gene editing nuclease regulation.

Targets: GLP-1, GIP, glucagon, amylin, PYY, leptin, IL-4, IL-13

Riboswitch Gene Regulation Platform · Eli Lilly and Company

Proprietary riboswitch technology enabling in vivo delivery of biologic therapeutics using oral small molecules; allows precise, dose-responsive gene expression regulation. Focus areas include metabolic peptides (GLP-1, GIP, glucagon, amylin, PYY, leptin), CAR-T cell therapy for liquid and solid tumors and autoimmune diseases, and PNS targets for intractable pain.

Riboswitch Gene Regulation Technology

Broadly applicable platform enabling precise, dose-responsive in vivo control of gene expression via oral small molecules; can be incorporated into any vector (AAV, lentivirus, CRISPR, LNPs); disease focus includes metabolic diseases (GLP-1, GIP, Glucagon, Amylin, PYY, Leptin), neuropathic pain (PNS targets), CAR-T for liquid/solid tumors, and autoimmune diseases

Riboswitch

Gene regulation technology platform enabling precise, dose-responsive in vivo control of any biologic therapeutic transgene expression via daily oral small molecule; applications include metabolic peptides (GLP-1, GIP, Glucagon, Amylin, PYY, Leptin), CAR-T (liquid/solid tumors, autoimmune), and PNS targets for neuropathic pain. Delivered via AAV, lentivirus, CRISPR, or LNPs.

Targets: GLP-1, GIP, Glucagon, Amylin, PYY, Leptin

Capital (as filed)

Cash
$185M cash and cash equivalents · Sep 30, 2026 (10-Q)
Long-term investments
$36.0M Sep 30, 2026
Operating cash flow
−$24.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$216M cash, runway mid-2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on MeiraGTx, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch MeiraGTx Holdings (MGTX) — Scientific Deep Dive for AAV-hAQP1, Bota-vec, AAV-GAD and Pipeline Products The AQP1 mechanism is elegant and human-validated but three of four 'pivotal' programs rest on failed, per-protocol or compassionate-use datasets, and the fourth is 24 open-label patients scored on an instrument with no validated threshold; revisit on AQUAx2 readout, a sub-$9 print, or Hologen payment confirmation.
  2. Watch UPDATE: MeiraGTx (MGTX) - The Raise I Said Was Coming The predicted equity raise arrived via a new $100M ATM, Hologen's $95M remains unpaid, and none of the three stated upgrade triggers (Hologen payment, AQUAx2 readout, sub-$9 print) has fired, so the watch stance is maintained.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 23, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)